Package Leaflet: Information for the User
Telzir 50 mg/ml Oral Suspension
fosamprenavir
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack and other information
Telzir is used to treat HIV (Human Immunodeficiency Virus) infection.
Telzir is a type of medicine known as an antiretroviral. Telzir is taken with low doses of another medicine, ritonavir, which increases the levels of Telzir in the blood. Telzir belongs to a group of antiretroviral medicines called protease inhibitors. Protease is an enzyme produced by HIV that enables the virus to multiply in the blood (in CD4 cells). By blocking the action of protease, Telzir stops the multiplication of HIV and the infection of more CD4 cells.
Telzir given with low doses of ritonavir is used in combination with other antiretroviral medicines (combination therapy) for the treatment of adults, adolescents, and children over 6 years of age infected with HIV.
HIV can become resistant to anti-HIV medicines. To avoid this happening, and to slow down the disease, it is very important that you continue to take all your medicines as your doctor has prescribed.
Telzir does not prevent the spread of HIV to other people. HIV is spread through sexual contact with an infected person, or through transfer of infected blood (for example, by sharing needles).
Telzir is taken in combination with low doses of ritonavir and other antiretroviral agents.Therefore, it is important that you carefully read the package leaflet provided with this medicine. If you have any further questions about ritonavir or the other prescribed medicines, please consult your doctor or pharmacist.
Do not take Telzir
Tell your doctorif you are in any of these situations.
Be careful with Telzir
Consult your doctor or pharmacist before you start taking Telzir:
Some patients may also develop diabetes during treatment with these medicines.
Tell your doctor if you are in any of these situations.While taking this medicine, you will require extra check-ups, including blood tests.
Your doctor will check your blood sugar levels before and during treatment with Telzir.
Be aware of important symptoms
Some patients taking medicines for HIV infection develop other symptoms, which can be serious.
These can be:
It is important that you know the signs and symptoms that may appear while taking Telzir.
Please read the information on “Other side effects of combination therapy for HIV” in section 4 of this leaflet.If you have any questions about this information or the advice given:
Consult your doctor.
You may experience skin rash
However, if you develop a skin rash, you can continue taking Telzir. You can be treated with antihistamines. Rarely, the skin rash can be severe and serious (Stevens-Johnson syndrome). If this happens, you must stop taking Telzir immediately and never take it again.
Other medicines and Telzir
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines,including herbal medicines or those bought without a prescription. Your doctor will decide if these medicines are suitable for you to take with Telzir and ritonavir. This is veryimportant, as taking certain types of medicines at the same time as Telzir and ritonavir can increase or decrease the effect of other medicines. This can, in some cases, cause serious problems.
There are some medicines that must not be taken with Telzir.You must check the list of medicines in the section “Do not take Telzir” at the beginning of section 2 of this leaflet.
The following medicines are not recommended to be taken with Telzir/ritonavir:
You will require close monitoring if you are taking the following medicines with Telzir/ritonavir:
It may be necessary to change your dose of Telzir if you are taking
Hormonal contraception
Taking Telzir and ritonavir while taking the contraceptive pill may damage your liver and may make the contraceptive less effective.
Use a non-hormonal contraceptive method such as a condom.
No studies have been performed on the use of Telzir/ritonavir with other hormonal therapies, such as hormone replacement therapy (HRT).
Taking Telzir with food and drinks
Adultsshould take Telzir oral suspension withoutfood and on an empty stomach.
Children and adolescentsshould take Telzir oral suspension withfood.
Pregnancy
If you are pregnant, think you may be pregnant, or are planning to have a baby:
Consult your doctor or pharmacistbefore using this medicine.
Breast-feeding
It is not recommendedthat HIV-infected women breast-feed their babies because HIV can be transmitted through breast milk. It is not known whether the components of Telzir can pass into breast milk. If you are breast-feeding or thinking of breast-feeding, consult your doctor as soon as possible.
Important information about some of the ingredients of Telzir oral suspension
Telzir oral suspension contains propyl hydroxybenzoate and methyl hydroxybenzoate. These ingredients may cause allergic reactions (which may be delayed).
Driving and using machines
Telzir may make you feel dizzy and cause other effects that reduce your alertness.
Do not drive or operate machinery or toolsunless you feel well.
Keep in regular contact with your doctor
Telzir helps to control your disease but does not cure HIV infection. You must continue to take it every day to avoid your disease getting worse. You may still develop other infections and illnesses associated with HIV.
Keep in touch with your doctor and do not stop taking Telzirwithout your doctor's advice.
Follow exactly the instructions for taking this medicine given by your doctor. It is very important that you take the complete daily dose of Telzir and ritonavir as your doctor has prescribed. Do not take morethan the recommended dose. If you are unsure, consult your doctor or pharmacist again.
Shake the bottle for 20 seconds before using it for the first time. Shake the bottle for 5 seconds before use on subsequent occasions.
A 10 ml graduated dosing syringe is included in the pack to measure the dose accurately.
Adults
Adultsshould take Telzir oral suspension withoutfood and on an empty stomach. The recommended dose is 14 ml of Telzir oral suspension(700 mg of fosamprenavir) twice a daywith 100 mg of ritonavir (in capsules or oral solution) twice a day.
Children over 6 years of age and weighing at least 25 kg
Childrenin this group should take Telzir oral suspension withfood.
Your doctor will tell you the correct dose based on weight.
The recommended dose is 0.36 ml/kgof Telzir oral suspension (which corresponds to 18 mg/kg of fosamprenavir) twice a daywith 3 mg/kg of ritonavir oral solution twice a day.
No dose recommendations can be made for children weighing less than 25 kg.
Children may take the adult dose of ritonavir capsules (100 mg twice a day) if they weigh at least 33 kg and can swallow the capsules whole.
As an alternative to Telzir oral suspension:
Children may take the adult dose of a 700 mg Telzir tablet twice a day(with 100 mg of ritonavir twice a day), if they weigh at least 39 kg and can swallow the tablets whole.
Children under 6 years of age
Telzir is not recommended for children under 6 years of age.
Adults with liver disease
If you have mild liver disease, the dose is 14 ml of Telzir oral suspension(700 mg of fosamprenavir) twice a daywith 100 mg of ritonavir only once a day. If you have moderate liver disease, the dose is 9 ml of Telzir oral suspension(450 mg of fosamprenavir) twice a day with 100 mg of ritonavir only once a day. If you have severe liver disease, the dose is 6 ml of Telzir oral suspension(300 mg of fosamprenavir) twice a day with 100 mg of ritonavir only once a day.
Step-by-step instructions
Do not mix Telzir with other medicines in the bottle or syringe.
If you take more Telzir than you should
If you take more Telzir than your doctor prescribed:
Consult your doctor or pharmacist immediately.
If you forget to take Telzir
If you forget to take a dose of Telzir, take it as soon as you remember and then continue your treatment as before. Do not take a double dose to make up for forgotten doses.
Do not stop taking Telzir without your doctor's advice
Take Telzir for as long as your doctor recommends. Do not stop treatment unless your doctor advises you to.
During HIV treatment, there may be an increase in weight and levels of glucose and lipids in the blood. This may be partly related to the recovery of health and lifestyle, and in the case of blood lipids, sometimes to HIV medications themselves. Your doctor will monitor these changes.
Like all medications, this medication may produce adverse effects, although not all people will experience them. When treating an HIV infection, it is not always possible to determine if some of the adverse effects that appear are caused by Telzir, by other medications taken at the same time, or by the HIV infection. For this reason, it is very important that you inform your doctor about any change that occurs in your health.
Very Common Adverse Effects
May affect more than 1 in 10 people treated:
Common Adverse Effects
May affect up to 1 in 10 people treated:
Uncommon Adverse Effects
May affect up to 1 in 100 people treated:
Rare Adverse Effects
May affect up to 1 in 1,000 people treated:
You may experience muscle problems
There have been reports of muscle pain, increased sensitivity, or weakness in the muscles, particularly with antiretroviral treatments that include protease inhibitors and nucleoside analogs. In rare cases, these muscle problems have been severe (rhabdomyolysis). If you notice muscle problems:
?Tell your doctor.
Patients with hemophilia may bleed more
In patients with hemophilia A and B, increased bleeding has been observed while being treated with protease inhibitors. If this happens to you:
?Consult your doctor immediately.
If you experience adverse effects
?Consult your doctor or pharmacist, even if it's an adverse effect that is not listed in this prospectus.
Other Adverse Effects of HIV Treatment
Reappearance of previous infections
Patients with advanced HIV infection (AIDS) have a weakened immune system and are more prone to developing severe infections (opportunistic infections). When these patients start treatment, it may happen that previous infections recur, causing signs and symptoms of inflammation. These symptoms are likely caused by the immune system becoming more potent and starting to fight these infections.
In addition to opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also appear after you start taking medications for your HIV treatment. Autoimmune disorders can appear many months after starting treatment. If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness that starts in the hands and feet and moves up to the torso, palpitations, tremors, or hyperactivity, inform your doctor immediately to receive the necessary treatment.
If you have any symptoms of infection or signs of inflammation while taking Telzir:
?Tell your doctor immediately. Do not take other medications for the infectionwithout consulting your doctor.
You may experience bone problems
Some patients on combined antiretroviral therapy for HIV develop osteonecrosis. In this condition, parts of the bone tissue die due to reduced blood supply to the bones.
Patients may be more likely to experience this condition:
Be especially cautious if you notice:
If you detect any of these symptoms:
?Tell your doctor.
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it's a possible adverse effect that is not listed in this prospectus. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of sight and reach of children.
Do not freeze. Telzir does not require special storage conditions.
Do not use this medication after the expiration date on the box and bottle.
Discard the bottle 28 days after it was first opened, but do not throw the medication down the drain or in the trash. Ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.
Composition of Telzir
Appearance of the Product and Package Contents
Telzir is supplied in plastic bottles containing 225 ml of oral suspension. The package includes a 10 ml graduated syringe and an adapter. The suspension is white to off-white in color.
Telzir is also available in film-coated tablets with 700 mg.
Marketing Authorization Holder and Manufacturer
Manufacturer | Marketing Authorization Holder |
ViiV Healthcare Trading Services UK Limited 12 Riverwalk, Citywest Business Campus Dublin 24, Ireland | ViiV Healthcare BV Van Asch van Wijckstraat 55H 3811 LP Amersfoort Netherlands |
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
België/Belgique/Belgien ViiV Healthcare srl/bv Tél/Tel: + 32 (0) 10 85 65 00 | Lietuva ViiV Healthcare BV Tel: +370 80000334 |
???????? ViiV Healthcare BV Te?.: +359 80018205 | Luxembourg/Luxemburg ViiV Healthcare srl/bv Belgique/Belgien Tél/Tel: + 32 (0) 10 85 65 00 |
Ceská republika GlaxoSmithKline s.r.o. Tel: + 420 222 001 111 cz.info @gsk.com | Magyarország ViiV Healthcare BV Tel.: +36 80088309 |
Danmark GlaxoSmithKline Pharma A/S Tlf: + 45 36 35 91 00 dk-info@gsk.com | Malta ViiV Healthcare BV Tel: +356 80065004 |
Deutschland ViiV Healthcare GmbH Tel.: + 49 (0)89 203 0038-10 viiv.med.info@viivhealthcare.com | Nederland ViiV Healthcare BV Tel: + 31 (0) 33 2081199 |
Eesti ViiV Healthcare BV Tel: +372 8002640 | Norge GlaxoSmithKline AS Tlf: + 47 22 70 20 00 |
Ελλ?δα GlaxoSmithKline Μονοπρ?σωπη A.E.B.E. Τηλ: + 30 210 68 82 100 | Österreich GlaxoSmithKline Pharma GmbH Tel: + 43 (0)1 97075 0 at.info@gsk.com |
España Laboratorios ViiV Healthcare, S.L. Tel: + 34 900 923 501 es-ci@viivhealthcare.com | Polska GSK Services Sp. z o.o. Tel.: + 48 (0)22 576 9000 |
France ViiV Healthcare SAS Tél: + 33 (0)1 39 17 6969 Infomed@viivhealthcare.com | Portugal VIIVHIV HEALTHCARE, UNIPESSOAL, LDA. Tel: + 351 21 094 08 01 viiv.fi.pt@viivhealthcare.com |
Hrvatska ViiV Healthcare BV Tel: +385 800787089 | România ViiV Healthcare BV Tel: +40 800672524 |
Ireland GlaxoSmithKline (Ireland) Limited Tel: + 353 (0)1 4955000 | Slovenija ViiV Healthcare BV Tel: +386 80688869 |
Ísland Vistor hf. Sími: +354 535 7000 | Slovenská republika ViiV Healthcare BV Tel: +421 800500589 |
Italia ViiV Healthcare S.r.l. Tel: + 39 (0)45 7741600 | Suomi/Finland GlaxoSmithKline Oy Puh/Tel: + 358 (0)10 30 30 30 Finland.tuoteinfo@gsk.com |
Κ?προς ViiV Healthcare BV Τηλ: +357 80070017 | Sverige GlaxoSmithKline AB Tel: + 46 (0)8 638 93 00 info.produkt@gsk.com |
Latvija ViiV Healthcare BV Tel: +371 80205045 | United Kingdom (Northern Ireland) ViiV Healthcare BV Tel: + 44 (0)800 221441 customercontactuk@gsk.com |
Date of the last revision of this prospectus:
Detailed information about this medication is available on the European Medicines Agency website: http://www.ema.europa.eu.